- Home
- ILAG vs SNGX Comparison
ILAG vs SNGX Comparison
Compare ILAG & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- SNGX
- Stock Information
- Founded
- ILAG 1981
- SNGX 1987
- Country
- ILAG Hong Kong
- SNGX United States
- Employees
- ILAG N/A
- SNGX N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- SNGX Health Care
- Exchange
- ILAG Nasdaq
- SNGX Nasdaq
- Market Cap
- ILAG 8.1M
- SNGX 6.5M
- IPO Year
- ILAG 2022
- SNGX 1987
- Fundamental
- Price
- ILAG $0.46
- SNGX $1.93
- Analyst Decision
- ILAG
- SNGX
- Analyst Count
- ILAG 0
- SNGX 0
- Target Price
- ILAG N/A
- SNGX N/A
- AVG Volume (30 Days)
- ILAG 4.1M
- SNGX 18.4K
- Earning Date
- ILAG 06-17-2025
- SNGX 05-09-2025
- Dividend Yield
- ILAG N/A
- SNGX N/A
- EPS Growth
- ILAG N/A
- SNGX N/A
- EPS
- ILAG N/A
- SNGX N/A
- Revenue
- ILAG $7,506,551.00
- SNGX $2,342.00
- Revenue This Year
- ILAG N/A
- SNGX N/A
- Revenue Next Year
- ILAG N/A
- SNGX N/A
- P/E Ratio
- ILAG N/A
- SNGX N/A
- Revenue Growth
- ILAG 16.50
- SNGX N/A
- 52 Week Low
- ILAG $0.34
- SNGX $1.68
- 52 Week High
- ILAG $1.35
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- ILAG 61.29
- SNGX 49.95
- Support Level
- ILAG $0.38
- SNGX $1.86
- Resistance Level
- ILAG $0.44
- SNGX $1.97
- Average True Range (ATR)
- ILAG 0.08
- SNGX 0.09
- MACD
- ILAG 0.00
- SNGX 0.01
- Stochastic Oscillator
- ILAG 23.70
- SNGX 70.59
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).